On November 6, 2025 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, reported that Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference being held from December 2-4, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the event are as follows:

Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat on Wednesday, December 3, 2025 at 10:50 AM ET, and members of management will be available for 1X1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

(Press release, AN2 Therapeutics, NOV 6, 2025, View Source [SID1234659617])

On November 6, 2025 Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory diseases, reported the upcoming presentation of preclinical data for its first-in-class, wild-type–sparing JAK2-JH2/V617F inhibitor ZE74-0282 at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. The company also confirmed plans to initiate first-in-human clinical studies in December 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Background

The JAK2 V617F mutation is the most common recurring driver mutation in classical myeloproliferative neoplasms (MPNs)—including polycythemia vera, essential thrombocytosis, and myelofibrosis—and is also present in subsets of other myeloid malignancies. The mutation, located in the JH2 pseudokinase domain, causes constitutive hyperactivation of JAK2 signaling.

Approved JAK inhibitors such as ruxolitinib and fedratinib target the JH1 kinase domain, offering symptomatic relief but lacking selectivity for the mutant form. This non-selective inhibition disrupts wild-type (WT) JAK2 signaling essential for normal hematopoiesis, limiting both long-term efficacy and tolerability.

About ZE74-0282

ZE74-0282 is a novel, small-molecule inhibitor rationally designed through in-silico and AI-driven molecular pharmacology to selectively target the JH2 domain of mutant JAK2 V617F while sparing WT JAK2 and other JAK family kinases.

Key non-clinical findings include:

Picomolar potency and > 500-fold selectivity for JAK2 V617F JH2 versus WT JAK2 JH2 in cellular assays.
100× selective inhibition of pSTAT5 phosphorylation and proliferation in BaF3 JAK2 V617F and SET-2 JAK2 V617F cells, with minimal effect on WT cells.
Nanomolar potency in selectively reducing pSTAT5 in myeloid cells from human JAK2 V617F⁺ MPN whole-blood assays, with no effect on lymphoid cells—confirming wild-type sparing. In contrast, ruxolitinib suppressed signaling across both lineages.
Selective inhibition of colony formation from JAK2 V617F/ASXL1-mutant progenitors, without affecting WT JAK2 progenitors, in murine colony-forming assays.
Superior tumor growth inhibition and stronger in-vivo pSTAT5 suppression compared with fedratinib in xenograft models.
Linear pharmacokinetics and toxicokinetics in DRF and GLP toxicology studies, demonstrating safety, tolerability, and a broad therapeutic window supporting optimal clinical dose selection.
Conclusion

ZE74-0282 is the first-in-class, JH2-domain–specific JAK2 inhibitor that selectively targets mutant JAK2 V617F while preserving normal JAK2-mediated hematopoietic signaling. Its differentiated selectivity profile and favorable pharmacology indicate a superior therapeutic index compared with JH1-directed inhibitors. These data support ZE74-0282 as a potentially disease-modifying therapy for patients with JAK2 V617F-driven myeloproliferative disorders.

Eilean Therapeutics plans to initiate its first-in-human clinical study of ZE74-0282 in December 2025.

(Press release, Eilean Therapeutics, NOV 6, 2025, View Source [SID1234659616])

On November 6, 2025 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported financial results for the third quarter ended September 30, 2025, and provided recent corporate progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The third quarter was marked by executional focus, and we remain on track with our planned IND filings for HWK-007 and HWK-016 by the end of the year. We continue to deploy capital efficiently, maintaining strong financial discipline as we prepare to enter the clinic and deliver potentially value-creating milestones," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "I’m proud of our role in adding to the scientific understanding of PTK7 with the data we presented at AACR (Free AACR Whitepaper)-NCI-EORTC. Confirming PTK7 as the third most highly expressed tumor marker among clinically validated and emerging ADC targets, these data underscore the tremendous opportunity we have with our first ADC candidate, HWK-007, to make a difference for the nearly 750,000 patients in the US with PTK7-expressing cancers."

Recent Operational Highlights:

Presented real-world analysis at AACR (Free AACR Whitepaper)-NCI-EORTC confirming PTK7 as a broadly expressed, clinically relevant target across solid tumors. The analysis was part of a collaboration between Whitehawk and Tempus AI.

On track to bring all three assets to IND by mid-2026. IND submissions are planned by year-end 2025 for HWK-007 and HWK-016. An IND for HWK-206 is expected by mid-2026.

Focused execution and capital efficiency support anticipated runway into 2028. Based on current plans, cash position enables initial clinical data readouts across the portfolio.
Third Quarter 2025 Financial Results:

Cash, cash equivalents and short-term investments as of September 30, 2025, were $162.6 million as compared to $47.2 million as of December 31, 2024. Cash is anticipated to fund operations into 2028 based on current plans.

Net loss for the three months ended September 30, 2025, was $17.7 million as compared to $12.5 million for the three months ended September 30, 2024.

(Press release, Whitehawk Therapeutics, NOV 6, 2025, View Source [SID1234659615])

On November 6, 2025 Servier reported that it will present new and updated data at the 67th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), December 6-9, 2025, in Orlando, Florida. Presentations will highlight clinical and real-world data from Servier’s hematology portfolio and underscore Servier’s leadership in isocitrate dehydrogenase (IDH) mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Notably, Servier will present an updated response and safety analysis from a Phase 1 study of TIBSOVO (ivosidenib) combined with intensive chemotherapy in newly diagnosed IDH1-mutated AML in an oral presentation on Monday, December 8 at 4:45 p.m. The data demonstrate the addition of TIBSOVO to intensive induction and consolidation chemotherapy followed by single-agent TIBSOVO maintenance produces long-term responses with an acceptable safety profile. The benefit of this frontline regimen is being assessed in a Phase 3 randomized, blinded trial.

"Servier’s presentations at this year’s ASH (Free ASH Whitepaper) Annual Meeting reflect our ongoing commitment to maximizing the potential of the medicines in our portfolio, leaving no stone unturned as we endeavor to deliver innovative treatment options to as many eligible patients as possible, said Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals. "We’re expanding our existing understanding of the clinical benefits of TIBSOVO to uncover its full potential in AML and MDS, while simultaneously advancing the research and development of investigational treatment options in our growing hematology pipeline."

(Press release, Servier, NOV 6, 2025, https://www.prnewswire.com/news-releases/serviers-new-and-updated-data-at-2025-ash-annual-meeting-highlight-commitment-to-hematology-research-302606336.html [SID1234659614])

On November 6, 2025 Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, reported that four abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to add to our body of clinical evidence. At SABCS 2025, we look forward to four poster presentations highlighting findings from studies evaluating the use of (Z)-endoxifen to advance breast cancer treatment and prevention," said Dr. Steven Quay, Atossa Therapeutics President and Chief Executive Officer.

Poster Presentation Details:

Title:

Initial results from RECAST DCIS: Multicenter platform trial testing active
surveillance and novel endocrine therapy agents for DCIS management

Date/Time:

Thursday, December 11, 2025, 12:30pm – 2:00pm CT

Title:

Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot

Date/Time:

Thursday, December 11, 2025, 12:30pm – 2:00pm CT

Title:

(Z)-Endoxifen Maintains ERα Antagonist Function Against ESR1 Mutants via
Inactive Conformation Stabilization and Reversal of Mutant ESR1-Associated
Transcriptional Signatures

Date/Time:

Friday, December 12, 2025, 7:00am – 8:30am CT

Title:

A Randomized Phase 2 Non-Inferiority Trial of (Z)-Endoxifen + Goserelin vs Exemestane + Goserelin as Neoadjuvant Treatment for
Premenopausal Women with ER+/HER2- Breast Cancer (EVANGELINE)

Date/Time:

Friday, December 12, 2025, 12:30pm – 2:00pm CT

(Press release, Atossa Therapeutics, NOV 6, 2025, View Source [SID1234659613])